Thermo Fisher Scientific SARS-CoV-2 Spike Protein (S1/S2) Recombinant Human Monoclonal Antibody (bcb03)

Applications

Western Blot (WB)

• Tested Dilution: 1:4,000–1:5,000
• View 1 publication

ELISA

• Tested Dilution: 1:80,000
• View publication

Neutralization (Neu)

• Tested Dilution: Assay-dependent
• View publication

Product Specifications

Product Specific Information

• Purity: Greater than 95% as determined by reducing SDS-PAGE
• Target: Specificity for Spike protein regions S1/S2, RBD, and ECD.

Target Information

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), also known as 2019-nCoV, causes illnesses ranging from mild cold symptoms to severe respiratory distress and death. The CoV Spike (S) protein is crucial for viral attachment, fusion, and entry, making it a key target for antibody and vaccine development.
The Spike protein receptor-binding domain (RBD, S-RBD) binds strongly to human and bat ACE2 receptors, showing higher affinity than SARS-CoV RBD.
S1 contains the RBD that specifically binds to ACE2 receptors on target cells. SARS-CoV-2 S consists of 1273 amino acids, including:

• Signal peptide (1–13 aa)
• S1 subunit (14–685 aa)
• S2 subunit (686–1273 aa)

The S-ECD represents the extracellular domain of the Spike protein.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.